- Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C32014 | Faculty of Pharmacy in Hradec Králové
- Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism2021 | Faculty of Pharmacy in Hradec Králové
- Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile2018 | Faculty of Pharmacy in Hradec Králové
- Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C32019 | Faculty of Pharmacy in Hradec Králové
- AKR1C3 Inhibitory Potency of Naturally-occurring Amaryllidaceae Alkaloids of Different Structural Types2017 | Faculty of Pharmacy in Hradec Králové
- Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters2022 | Faculty of Pharmacy in Hradec Králové
- Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment2018 | Faculty of Pharmacy in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Faculty of Pharmacy in Hradec Králové
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters2019 | Faculty of Pharmacy in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové